On Tuesday 19th September 2017, Andreas Kleppe defended his dissertation for the degree of Ph.D. at the Institute for Informatics at the University of Oslo. Colleagues and family were greatly impressed by the young Doctor who will continue his work at our Institute.
The trial lecture was entitled "Challenges and opportunities in digital pathology of tomorrow regarding multimodal data collection, machine learning and validation”. The topic of the dissertation was:
"Automatic detection of aberrant chromatin structure predicts prognosis in several cancer types".
Congratulations Dr. Kleppe!
Better knowledge base for treatment of endometrial cancer
Manohar Pradhan is a pathologist and one of our many great researchers. He has recently published a paper in Gynecologic Oncology, in collaboration with colleagues from the ICGI, the University of British Columbia and the University of Oxford. The findings reported will contribute to a better knowledge base for the choice of treatment for women with endometrial cancer.
Please find the article here: Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). Endometrial cancer is sometimes loosely referred to as "uterine cancer", although it is distinct from other forms of uterine cancer such as cervical cancer, uterine sarcoma, and trophoblastic disease. The most frequent type of endometrial cancer is endometrioid carcinoma, which accounts for more than 80% of cases. Endometrial cancer is commonly diagnosed by endometrial biopsy or by taking samples during a procedure known as dilation and curettage. Though the five-year-survival rate after being diagnosed with endometrial cancer is >90%, this cancer type is the third most common cause of death in cancers which only affect women.
Doing More in Prognosis and Diagnosis
The ICGI is part of Oslo Cancer Cluster. Their story about ICGl, DoMore! and the significance of new technology development in the fight against cancer was published on their website during the summer of 2017.
Please click here to read the full article.
CCC accreditation for OUH
We are so proud to be able to tell that The European Cancer Institute has given Oslo University Hospital (OUS) status as a Comprehensive Cancer Center (CCC). Accreditation is provided for the hospital's total cancer activity and includes all clinics and departments involved in the diagnosis and treatment of cancer. The ICGI has participated in groups, teams and boards at Oslo University Hospital who through tedious work, over a long period of time, have made this possible.
About the DoMore! project in Science Nordic
An article about our research project DoMore! is now published in English, on the Science Nordic website. This is following recent articles in norwegian which may be found on our norwegian newsroom "myNewsDewsk".
View our strategy document online
We have recently completed the presentation folder containing the Institute's strategy for the next five years. This is a document we are proud of, where both text and images present our diversity, strengths and focus areas.
Please contact us or drop by if you would like a paper copy.
The pdf of the document may be viewed online by clickinghere.
Third CRC Network meeting
The CRC Network is an international network of researchers aiming to improve diagnosis, research and medical treatment of colon- and rectum cancer with emphasis on increased understanding of genetic mechanisms.
The inaugural of the Oxford Centre for Cancer Gene Research at the University of Oxford, and the third meeting for the CRC Network will take place in the historic settings of the Queen's College on the 30th and 31st March 2017.
Specially invited speakers, among them some of the world's finest researchers, will present their latest achievements and research on colorectal cancer. This year's theme is Genome Stability and Instability in Cancer.
The lecture session is open to all interested in advances within research on colorectal cancer, and the event is now fully booked. Go to www.crcnetwork.net to read more about the CRC Network.
Marianne Lislerud Smebye will on the 17th of March 2017 defend her doctoral thesis "Transcriptomic consequences of chromosome 19 rearrangements in ovarian carcinomas".
The main aim of the PhD project has been to gain insight into the RNA-level consequences of these genomic rearrangements. Identification of such genes is important since they have great potential as cancer-specific tumor markers or as drug targets. We wish her good luck!
Announcement on the University of Oslo website: http://www.med.uio.no/klinmed/forskning/aktuelt/arrangementer/disputaser/2017/smebye-marianne-lislerud.html
A video explaining the DoMore! project
The ICGI at Oslo University Hospital was in 2016 awarded a prestigious Fyrtårn grant by the Norwegian Research Council for their project, titled “DoMore! : In silico Pathology - Improving diagnosis by utilizing Big Data and software-driven automation of pathology”.
The DoMore! project will run over the next five years under Institute Director Håvard Danielsen and aims to make advances in prognostication of cancer.
We are proud to present this short video explaining the project.
For more information, please see the www.domore.no website.
Marta Brunetti and colleagues paper in Oncotarget about vulvar cancer.
Vulvar cancer is the fourth most common gynecologic cancer accounting for 5% of all malignancies of the female genital tract. About 80 Norwegian woman are affected each year. Cytogenetic and molecular data on this type of cancer is limited. We are therefore proud to share young scientist Marta Brunetti's recent published paper in Oncotarget, written together with colleagues at the ICGI. The team has used new methods to investigate the genomic and transcriptomic changes present in a specific type of vulvar cancer. The findings shed more light into the mechanism behind the formation and progression of the tumor. Hopefully, in the future, they will be important for diagnosis and prognosis, and can even be a target for new therapeutics.
Read the article here.